Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00532675 · ClinicalTrials.gov registry record · Phase 1
Safety Study of LBH589 When Given in Combination With Lenalidomide and Dexamethasone in Adult Patients With Multiple Myeloma.
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
NCT00532675 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 46 participants.
The verdict
NCT00532675, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
Study Summary
This study will evaluate the safety of LBH589 given in combination with lenalidomide and dexamethasone in adult patients with multiple myeloma
Interventions
- COMBINATION_PRODUCT Lenalidomide
- DRUG LBH589
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2008-04-22 |
| Est. Completion | 2017-11-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00532675
The ClinicalTrials.gov registry entry for NCT00532675 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lenalidomide is the first listed.
NCT00532675 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00532675 about?
NCT00532675 is a clinical study titled "Safety Study of LBH589 When Given in Combination With Lenalidomide and Dexamethasone in Adult Patients With Multiple Myeloma.". This study will evaluate the safety of LBH589 given in combination with lenalidomide and dexamethasone in adult patients with multiple myeloma
What is the current status of trial NCT00532675?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2008-04-22. Estimated completion is 2017-11-08.
What interventions are being tested in trial NCT00532675?
The interventions under investigation include: Lenalidomide (COMBINATION_PRODUCT), LBH589 (DRUG).
Who is sponsoring clinical trial NCT00532675?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.